147 related articles for article (PubMed ID: 21622187)
1. An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.
Heylen E; Willemse J; Hendriks D
Front Biosci (Landmark Ed); 2011 Jun; 16(7):2427-50. PubMed ID: 21622187
[TBL] [Abstract][Full Text] [Related]
2. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
Claesen K; Mertens JC; Leenaerts D; Hendriks D
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477318
[TBL] [Abstract][Full Text] [Related]
3. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models.
Leenaerts D; Loyau S; Mertens JC; Boisseau W; Michel JB; Lambeir AM; Jandrot-Perrus M; Hendriks D
J Thromb Haemost; 2018 Oct; 16(10):2057-2069. PubMed ID: 30053349
[TBL] [Abstract][Full Text] [Related]
4. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.
Leurs J; Wissing BM; Nerme V; Schatteman K; Björquist P; Hendriks D
Thromb Haemost; 2003 Feb; 89(2):264-71. PubMed ID: 12574805
[TBL] [Abstract][Full Text] [Related]
5. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.
Leenaerts D; Aernouts J; Van Der Veken P; Sim Y; Lambeir AM; Hendriks D
Thromb Haemost; 2017 Jul; 117(8):1498-1508. PubMed ID: 28692110
[TBL] [Abstract][Full Text] [Related]
6. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?
Willemse JL; Heylen E; Nesheim ME; Hendriks DF
J Thromb Haemost; 2009 Dec; 7(12):1962-71. PubMed ID: 19719827
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.
Mertens JC; Claesen K; Leenaerts D; Sim Y; Lambeir AM; Hendriks D
J Thromb Haemost; 2019 Jun; 17(6):878-884. PubMed ID: 30887647
[TBL] [Abstract][Full Text] [Related]
8. A role for procarboxypepidase U (TAFI) in thrombosis.
Willemse JL; Hendriks DF
Front Biosci; 2007 Jan; 12():1973-87. PubMed ID: 17127436
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
Leenaerts D; Bosmans JM; van der Veken P; Sim Y; Lambeir AM; Hendriks D
J Thromb Haemost; 2015 Dec; 13(12):2227-32. PubMed ID: 26340515
[TBL] [Abstract][Full Text] [Related]
10. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.
Knecht W; Willemse J; Stenhamre H; Andersson M; Berntsson P; Furebring C; Harrysson A; Hager AC; Wissing BM; Hendriks D; Cronet P
FEBS J; 2006 Feb; 273(4):778-92. PubMed ID: 16441664
[TBL] [Abstract][Full Text] [Related]
11. Proteolytic activation of purified human procarboxypeptidase U.
Schatteman KA; Goossens FJ; Scharpé SS; Hendriks DF
Clin Chim Acta; 2000 Feb; 292(1-2):25-40. PubMed ID: 10686274
[TBL] [Abstract][Full Text] [Related]
12. Carboxypeptidase U at the interface between coagulation and fibrinolysis.
Schatteman K; Goossens F; Leurs J; Verkerk R; Scharpé S; Michiels JJ; Hendriks D
Clin Appl Thromb Hemost; 2001 Apr; 7(2):93-101. PubMed ID: 11292199
[TBL] [Abstract][Full Text] [Related]
13. Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study.
Claesen K; Mertens JC; Basir S; De Belder S; Maes J; Bosmans J; Stoffelen H; De Meester I; Hendriks D
Clin Ther; 2021 May; 43(5):908-916. PubMed ID: 33910760
[TBL] [Abstract][Full Text] [Related]
14. Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.
Willemse JL; Hendriks DF
Clin Chem; 2006 Jan; 52(1):30-6. PubMed ID: 16299049
[TBL] [Abstract][Full Text] [Related]
15. Plasmin and the thrombin-thrombomodulin complex both contribute to thrombin-activatable fibrinolysis inhibitor activation in whole blood model thrombi.
Vercauteren E; Mutch NJ; Declerck PJ; Gils A
J Thromb Haemost; 2013 Jan; 11(1):190-2. PubMed ID: 23140098
[No Abstract] [Full Text] [Related]
16. ProCPU Is Expressed by (Primary) Human Monocytes and Macrophages and Expression Differs between States of Differentiation and Activation.
Claesen K; De Loose J; Van Wielendaele P; De Bruyn E; Sim Y; Thys S; De Meester I; Hendriks D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835137
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
18. Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
Schaffner AP; Sansilvestri-Morel P; Despaux N; Ruano E; Persigand T; Rupin A; Mennecier P; Vallez MO; Raimbaud E; Desos P; Gloanec P
J Med Chem; 2021 Apr; 64(7):3897-3910. PubMed ID: 33764059
[TBL] [Abstract][Full Text] [Related]
19. Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease.
Leurs J; Hendriks D
Thromb Haemost; 2005 Sep; 94(3):471-87. PubMed ID: 16268459
[TBL] [Abstract][Full Text] [Related]
20. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
